|
|
|
| home > ict > Winter 2017 |
|
|
 PUBLICATIONS |
International Clinical Trials |
|
|
|
|
|
 |
| |
|
|
Editor’s Comment
With a wide range of topics from patient recruitment and retention to pharma after Brexit, there is a lot to discover in ICT February. Editor Dr Graham Hughes reflects on the most pressing matters.
|
|
|
|
|
Brexit and the EU Clinical Trials Regulation
Business as Usual?
In light of Brexit, SynteractHCR’s Dr Martine Dehlinger-Kremer discusses the EU’s new Clinical Trials Regulation and how the pharma industry could be affected.
|
|
|
Brexit and Clinical Trials
Life After Brexit
Dr Laura Brown at LB Training and Development contemplates the changes that the clinical trial landscape is set to encounter after the historic Brexit result. There will undoubtedly be some difficulties along the way, but the UK will also be presented with some new opportunities.
|
|
|
IT in Drug Development
Weave the Threads
Constantly changing regulations create difficulties for companies in getting their products to market faster. In order to accelerate drug development, Appian’s Evjatar Cohen suggests that achieving a single source of truth could be key.
|
|
|
End Point
Smaller World, Bigger Challenges
ICT Editor Dr Graham Hughes reports on the dramatic decrease in approved drugs since 2010, with one potential solution being the use of new chemical synthesis software.
|
|
|
|
Primary Care
Reality Check
CK Aspire’s Julie Millar, Gaynor Mates and Louise Doyle assess the role of the research nurse in real world studies for long-term medical conditions. The nurses are, they say, leading the way for recruitment and engagement.
|
|
|
Electronic Trial Master Files
Master the Art
According to Badr Fathi and Jens-Olaf Vanggaard at HighPoint Solutions, compliance should not be the main goal of the business when utilising eTMFs but rather the natural result of sustainable operational improvements.
|
|
|
|
Clinical Trial Labelling
A Surprise Package
PRISYM ID’s Mark Cusworth believes that a possible reason for low patient retention is the labelling of drugs. Often overlooked, problems associated with language and the sheer volume of information that must be included need to be addressed to improve subject attrition.
|
|
|
|
|
Regional Focus: Africa
Up and Coming
Despite the current challenges surrounding clinical trials in the region, Saravanan Thangaraj at Frost & Sullivan investigates why Sub-Saharan Africa could become an attractive study location as a result of continued regulatory and infrastructural advances.
|
|
|
|
|
RBM Adoption
Survey Time
In a bid to improve quality and efficiency, change management practice is coming to the fore. Nicole Stansbury at PPD explores the implementation of risk-based monitoring and how surveys among clinical staff are aiding in driving this approach forward.
|
|
|
|
Supply Chain Operations
Risky Move
The majority of pharma businesses rely on ICH guidelines to help mitigate risk in their supply chains. However, Mark Sawicki at Cryoport explains why this method needs to be re-evaluated in the wake of the shift from small molecule products to biologics and regenerative therapies.
|
|
|
|
|
Adaptive Trial Design
Out of Control
In light of recent epidemics, Sujay Jadhav at goBalto proposes a method to bypass the often lengthy clinical trial process. Innovative study designs are needed to ensure that vaccines are approved as soon as possible in times of emergency.
|
|
|
|
|
Patient Centricity
Focal Point
With ‘patient centricity’ being the current buzz term of the pharma industry, Bruno Gagnon and Nick Payton of Comprehend outline the advantages of this approach and illustrate how treating patients as consumers, rather than subjects, may be the answer that the sector has been looking for.
|
|
|
Patient Recruitment
Human Touch
Clinical staff can aid and influence patient enrolment targets in studies, according to Stewart Rosen and Nicola J Smith of QuintilesIMS. They examine the role of clinical trial educators and how it is set to evolve in the future.
|
|
|
|
|
Q&A: Global Compliance
Up in the Clouds
ICT talks to Michaeline Daboul from MMIS about current challenges faced by life sciences companies to comply with ever-evolving regulations, and how SaaS solution MediSpend® could help alleviate this burden.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Phenomenex Introduces bioZen Series for Characterization of Biotherapeutics
Torrance, Calif. (April 16, 2018) – Phenomenex Inc., a global leader in
the research and manufacture of advanced technologies for the separation
sciences, introduces bioZen – a new series of LC solutions for bioseparations
in pharmaceutical, biopharmaceutical and academic research. The series
encompasses both proven and entirely new media spanning two particle platforms
– core-shell and thermally modified fully porous – along with new biocompatible
titanium hardware. The initial bioZen product line features seven chemistries
for the UHPLC and HPLC characterization of biotherapeutics such as monoclonal
antibodies, antibody-drug conjugates and biosimilars. The offering includes
specific LC chemistries for the analysis of aggregates and total mAb, intact
mass and fragments, peptide mapping and quantitation and glycan mapping.
More info >> |
|
 |
White Papers |
 |
|
Clinical Research in Spain
BioClever
This whitepaper is on clinical research in Spain, giving a general outline of the main characteristics of research in this country and an overview of the applicable regulations, along with the reasons why Spain is a good place to do research.
More info >> |
|
 |
Industry Events |
 |
SMi’s 5th Molecular Diagnostics Conference
9-11 July 2018, Holiday Inn Kensington Forum, London, UK
SMi is proud to announce their 5th Molecular
Diagnostics conference. The event will take place in central London on Monday
9th and Tuesday 10th July 2018, along with two half-day post-conference
workshops taking place on Wednesday 11th July 2018
More info >> |
|
|
